Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$31.61 USD
+4.09 (14.86%)
Updated May 28, 2024 04:00 PM ET
After-Market: $31.63 +0.02 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 201 - 220 ( 221 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Two Data Readouts in 1H?15; Reiterating Market Outperform
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 2Q?14 EPS; Advancing CORT-125 in August
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 1Q?14 EPS; Lowering Price Target to $6
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C